Article metrics

Download PDFPDF

739 A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to October 2024

AbstractFullPdf
Nov 202255080754
Dec 2022232022
Jan 2023126011
Feb 2023122011
Mar 2023130011
Apr 202311405
May 20235204
Jun 20233003
Jul 20234009
Aug 20235006
Sep 20233005
Oct 20237203
Nov 202344010
Dec 20236805
Jan 20242601
Feb 20243401
Mar 20244407
Apr 20244405
May 20245204
Jun 20245204
Jul 202446012
Aug 202454019
Sep 20243606
Oct 20243006
Total70360924